Ectin Research AB is a pharmaceutical company focused on developing a groundbreaking treatment for metastatic urothelial bladder cancer. Their innovative drug candidate, MFA-370, is currently undergoing trials for the treatment of this aggressive form of cancer. Bladder cancer ranks as the fifth most common cancer in both Europe and the United States, with high social costs and a poor prognosis for patients with metastatic forms of the disease.

Existing treatments have limited efficacy and often come with severe side effects. Ectin's mission is to address these unmet needs and provide a more effective and tolerable treatment option for patients. MFA-370 has shown great promise in preclinical studies, demonstrating its ability to decrease cancer cell proliferation and induce cancer cell death.

Ectin aims to develop MFA-370 into a new standard treatment not only for third-line patients but also for individuals in lower treatment lines. Their vision is to offer an effective treatment with fewer side effects, administered in the patient's home to minimize disruption to their daily lives. By prioritizing patient well-being and reducing social costs, Ectin Research is at the forefront of revolutionizing bladder cancer treatment